Searchable abstracts of presentations at key conferences in endocrinology

ea0025p25 | Bone | SFEBES2011

Comparison of two high dose- bolus vitamin D regimens in women with low vitamin D levels

Charopoulos Ioannis , Orme Steve

Aim: To compare the efficacy, tolerability and safety of high doses of i.m. vitamin D2 (ergocalciferol) with oral vitamin D3 (colecalciferol) supplementation in women with low vitamin-D levels.Design and settings: Of 107 patients (s25(OH)D≤50 nmol/l), aged 21–89 years were recruited in a retrospective audit. Participants were separated in two groups according to serum vitamin D levels. The Group 1 included individuals wit...

ea0025p66 | Clinical biochemistry | SFEBES2011

Pituitary thyroid hormone resistance (PTHR)

El-Laboudi Ahmed , Orme Steve

A 32-year-old lady was referred to our centre with thyrotoxicosis and elevated FT4 and TSH levels. She was already on carbimazole. Interestingly, her symptoms started at childhood. She was nicknamed ‘shaky’ by her school friends because of her tremors. There was no family history of thyroid disease.She was clinically and biochemically thyrotoxic with FT4 of 12.4–38.8 pmol/l and TSH of 7.24–38.8 mIU/l.<p class...

ea0015p45 | Clinical practice/governance and case reports | SFEBES2008

Dopamine agonist therapy versus surgery in cystic macroprolactinoma

Mintnala Sirisha , Elmalti Akrem , Orme Steve

The efficacy of dopamine agonist therapy for complex solid and cystic macroprolactinoma is a subject of controversy among endocrinologists. Many believe that such therapy may not result in a clinically significant shrinkage of any cystic component of a macroprolactinomas.We present a case of cystic macroprolactinoma which responded damatically to dopaminergic therapy with recovery of pituitary function.A 22 years old male, presente...

ea0015p83 | Clinical practice/governance and case reports | SFEBES2008

Viable pregnancy associated with intrapartum rhGH replacement therapy

Swinburne Julie , Elmalti Akrem , Orme Steve

Growth hormone replacement has not been recommended for use during pregnancy, due to lack of controlled trials to study its effects on the mother and the baby. We present a patient with hypopitiutarism on rhGH replacement which was continued during pregnancy with no adverse effects.A 35 years old lady, diagnosed ages 30 with pan-hypopituitarism secondary to non-functioning pituitary adenoma, she underwent trans-sphenoidal resection of the adenoma in 2002...

ea0015p305 | Steroids | SFEBES2008

Testosterone levels in hypogonadal men treated with Nebido® is influenced by age, body composition and baseline testosterone

Moisey Robert , Swinburne Julie , orme Steve

Nebido (testosterone undecanoate, 1000 mg) is a new, long acting, intramuscular (IM) preparation of testosterone (T) that can be administered every 10–14 weeks. We conducted a study to evaluate the factors that influence serum T levels after commencing Nebido and may therefore help clinicians estimate dosing frequency for this therapy.Following the recommended loading regimen, 51 hypogonadal men (35, 68.6% secondary hypogonadism) had two injections ...

ea0013p8 | Bone | SFEBES2007

Case of parathyroid carcinoma with severe hungry bone syndrome

Rathi Manjusha , Ajjan Ramzi , Orme Steve

Introduction: In young patients with Primary hyperparathyroidism, parathyroidectomy is the treatment of choice. Transient hypocalcaemia is common complication of parathyroidectomy but rarely potentially life threatening hungry bone syndrome (HBS) can develop. HBS is a state of hypocalcaemia, hypophosphataemia and tetany without concomitant hypoparathyroidism, and is caused by massive calcium deposition to the bone. Resulting hypocalcaemia can be severe and prolonged, requiring...

ea0013p269 | Steroids | SFEBES2007

What factors influence serum testosterone levels when initiating Nebido®?

Moisey Robert , Swinburne Julie , Orme Steve

It is important when initiating intramuscular Nebido (testosterone undecanoate) to monitor the serum testosterone level to ensure physiological replacement is achieved. Following a loading regimen of Nebido the manufacturer recommends measuring testosterone levels to determine the frequency of subsequent injections.We conducted a retrospective study of 36 hypogonadal men [12 (33%) primary hypogonadism, 24 (67%) secondary hypogonadism] to establish what f...

ea0013p298 | Thyroid | SFEBES2007

Assessment and management of non-compliant hypothyroid patients: the role of weekly observed thyroxine therapy

Moisey Robert , Swinburne Julie , Orme Steve

There are a number of symptomatic patients with hypothyroidism who fail to normalise thyroid function (TFTs) despite large doses of thyroxine (LT4) replacement. Non-compliance is a common cause of treatment failure even in patients who strongly deny this. To avoid unnecessary and prolonged investigations for other causes we advocate a simple protocol to manage this problem. Patients are observed taking 1000 mcg of LT4 at 09.00 hrs, and have hourly Free T4 and TSH levels measur...

ea0031p64 | Clinical practice/governance and case reports | SFEBES2013

Conn's syndrome with normal plasma renin aldosterone ratio

Thida Myat , Andrews Julie , Barth Julian , Orme Steve

Background: Conn’s syndrome accounts for 35% of primary hyperaldosteronism. Elevated plasma aldosterone concentration to renin activity is widely used as a screening diagnostic tool. However, we report an unusual presentation of Conn’s syndrome with normal plasma renin aldosterone ratio.A 48-year-old man was seen in endocrine clinic with uncontrolled hypertension and severe hypokalemia. Primary hyperaldosteronism was suspected with blood pressu...

ea0025p97 | Clinical biochemistry | SFEBES2011

Hypercalcaemia following parathyroidectomy in a pregnant lady with MEN-1

King Rhodri , Ward Emma , Scarsbrook Andy , Orme Steve

We present a 20-year-old lady who was known to have MEN-1 and had previously been treated for hyperparathyroidism at a different hospital in 2003 with excision of right upper and lower and left lower parathyroid glands and left thyroid lobectomy, resulting in normalisation of adjusted calcium (adjCa) levels.She presented to our department with persistently elevated adjusted calcium levels (adjCa 2.69 mmol/l) along with raised parathyroid hormone (PTH 16 ...